Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection
ONCOVID-19
1 other identifier
observational
1,231
1 country
18
Brief Summary
National multicentre epidemiological study to describe retrospectively and prospectively the clinical outcomes of patients with a suspected coronavirus infection (either confirmed or not) while receiving a medical treatment for the underlying cancer
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Shorter than P25 for all trials
18 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 2, 2020
CompletedFirst Submitted
Initial submission to the registry
April 23, 2020
CompletedFirst Posted
Study publicly available on registry
April 27, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2020
CompletedJuly 1, 2020
June 1, 2020
3 months
April 23, 2020
June 30, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mortality of cancer patients under active anticancer treatment
Mortality rate, defined as the proportion of patients who are dead 28 days after the date of the diagnostic procedure for the 2 cohorts of patients (positive and negative).
28 days after the date of the diagnostic procedure
Secondary Outcomes (9)
Overall survival
6 months (i.e. at the the time of last patient last visit)
Hospitalizations
28 days after the date of the diagnostic procedure
Death
6 months (i.e. at the the time of last patient last visit)
Complications
28 days after the date of the diagnostic procedure
Hospitalizations
28 days after the date of the diagnostic procedure
- +4 more secondary outcomes
Eligibility Criteria
Patients with cancer in active phase of treatment suspected or diagnosed of a SARS-CoV-2 infection
You may qualify if:
- I1. Confirmed diagnosis of any type of solid or hematologic tumor;
- I3. Patient with suspicion of COVID-19 (clinical symptoms of COVID-19 including fever (\>38°C) and/or respiratory tract symptoms), either confirmed or not.
- Note 1: Patients must have underwent diagnostic procedures: diagnostic test (positive or negative) and/or chest imaging. Note 2: Patients will be eligible regardless of the presence of a neutropenia (either febrile or not) ;
- I4. Patient and/or family did not decline data collection after complete information.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (18)
Institut Bergonié
Bordeaux, France
Centre François Baclesse
Caen, 14076, France
Centre Hospitalier Métropole Savoie
Chambéry, 73011, France
Centre Jean Perrin
Clermont-Ferrand, 63011, France
Centre Georges François Leclerc
Dijon, 21079, France
Centre Oscar Lambret
Lille, 59020, France
Centre Leon Berard
Lyon, 69373, France
CH Annecy-Genevois
Metz-Tessy, 74370, France
Groupement Hospitalier Porte de Provence
Montélimar, 26216, France
Institut de Cancérologie de Montpellier
Montpellier, 34298, France
Centre Antoine Lacassagne
Nice, France
Centre Hospitalier Lyon-Sud
Pierre-Bénite, 69495, France
Institut Jean Godinot
Reims, 51726, France
Centre Henri Becquerel
Rouen, 76038, France
Institut de Cancérologie de l'Ouest
Saint-Herblain, 44805, France
Institut de cancérologie Strasbourg Europe (ICANS)
Strasbourg, 67033, France
Institut Universitaire du Cancer de Toulouse - IUCT Oncopole
Toulouse, 31059, France
CH Valence
Valence, France
Related Publications (1)
Assaad S, Zrounba P, Cropet C; ONCOVID-19 study Consortium; Blay JY. Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study. Br J Cancer. 2021 Aug;125(5):658-671. doi: 10.1038/s41416-021-01452-4. Epub 2021 Jun 16.
PMID: 34135471DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 1 Month
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 23, 2020
First Posted
April 27, 2020
Study Start
April 2, 2020
Primary Completion
June 30, 2020
Study Completion
June 30, 2020
Last Updated
July 1, 2020
Record last verified: 2020-06